Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P467: Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitisECCO '17 Barcelona
Year: 2017
Authors:

Panés J.*1, Rubin D.T.2, Vermeire S.3, Lindsay J.O.4, Sands B.E.5, Su C.6, Friedman G.6, Zhang H.6, Kayhan C.6, Manuchehri A.7, Healey P.8

1Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain 2The University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, IL, United States 3Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium 4Centre for Immunobiology, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom 5Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, United States 6Pfizer Inc, Collegeville, PA, United States 7Pfizer Ltd, Tadworth, United Kingdom 8Pfizer Inc, Groton, CT, United States

P468: Etrolizumab treatment improves histological activity as assessed by the Robarts histopathology indexECCO '17 Barcelona
Year: 2017
Authors:

Feagan B.G.1, De Hertogh G.2, Peyrin-Biroulet L.3, Rubin D.T.4, Maciuca R.5, McBride J.5, Arulmani U.*5, Scherl A.5

1University of Western Ontario, London, Canada 2University of Leuven, Leuven, Belgium 3Université de Lorraine, Vandœuvre-lès-Nancy, France 4University of Chicago Medicine, Chicago, United States 5Genentech, South San Francisco, United States

P469: Safety, tolerability, and pharmacokinetics of the intestine-restricted oral pan-Janus kinase inhibitor TD-1473 after single and multiple oral doses in healthy subjectsECCO '17 Barcelona
Year: 2017
Authors:

Ferslew B.*1, Sherman C.2, Nguyen D.3, Graham R.1

1Theravance Biopharma, Clinical Pharmacology and DMPK, South San Francisco, United States 2Theravance Biopharma, Biostatistics, South San Francisco, United States 3Theravance Biopharma, Clinical Development, South San Francisco, United States

P470: Comparative effectiveness analysis of flares, hospitalisations, and corticosteroid use among biologic naïve patients with inflammatory bowel disease within 12 months of initiation of vedolizumab or infliximabECCO '17 Barcelona
Year: 2017
Authors:

Alam N.1, Raluy-Callado M.1, Gardstein B.2, Curtis R.3, Khalid J.M.*3

1Evidera, London, United Kingdom 2Evidera, Waltham, United States 3Takeda Development Centre Europe Ltd., London, United Kingdom

P471: Efficacy and safety of switching from reference infliximab to biosimilar infliximab in patients with inflammatory bowel disease: first French experienceECCO '17 Barcelona
Year: 2017
Authors:

Soret P.-A.*1,2, Prieux-Klotz C.1, Avouac J.3, Molto A.3, Dior M.1, Brieau B.1, Dreanic J.1, Camus M.1, Barret M.1, Coriat R.1, Conort O.4, Chast F.4, Goulvestre C.5, Le Jeunne C.6, Dougados M.3, Nahon S.2, Chaussade S.1, Abitbol V.1

1Cochin Hospital, Department of Gastroenterology, Paris, France 2Le Raincy-Montfermeil Hospital, Department of Gastroenterology, Montfermeil, France 3Cochin Hospital, Department of Rheumatology, Paris, France 4Cochin Hospital, Department of Pharmacy, Paris, France 5Cochin Hospital, Department of Biology, Paris, France 6Cochin Hospital, Department of Internal Medicine, Paris, France

P472: Original and biosimilar infliximab: Are they two faces of the same coin? The experience from a pioneer European centerECCO '17 Barcelona
Year: 2017
Authors:

Cúrdia Gonçalves T.*1, Monteiro S.1, Dias de Castro F.1, Moreira M.J.1, Cotter J.1,2,3

1Hospital da Senhora da Oliveira, Gastroenterology, Guimarães, Portugal 2University of Minho, Life and Health Sciences Research Institute, School of Medicine, Braga, Portugal 3ICVS/3B's, PT Government Associate Laboratory, Braga/Guimarães, Portugal

P473: How to monitor the withdrawal of maintenance treatment with azathioprine in IBD patients with deep remission: results from a prospective study on multiple non invasive testsECCO '17 Barcelona
Year: 2017
Authors:

Cassinotti A.*1, Massari A.1, Carmagnola S.1, Molteni P.1, Fociani P.2, Ardizzone S.1

1ASST Fatebenefratelli Sacco, Luigi Sacco University Hospital, Gastroenterology Unit, Milan, Italy 2ASST Fatebenefratelli Sacco, Luigi Sacco University Hospital, Pathology Unit, Milan, Italy

P474: An enzyme-linked immunosorbent assay for therapeutic drug monitoring of vedolizumabECCO '17 Barcelona
Year: 2017
Authors:

Berger C.1, Semmler J.1, Ruppert J.1, Schulze H.2, Armbruster F.-P.1, Dignass A.2,3, Stein J.*3,4

1Immundiagnostik AG, Bensheim, Germany 2Agaplesion Markus Krankenhaus, Frankfurt/Main, Germany 3Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt/Main, Germany 4DGD Clinics Sachsenhausen, Frankfurt/Main, Germany

P475: Switching from infliximab originator to CT-P13 is not related to increased immunogenicity in IBD patients: a prospective case-control studyECCO '17 Barcelona
Year: 2017
Authors:

Fiorino G.*1, Radice S.1, Gilardi D.1, Correale C.1, Allocca M.1, Furfaro F.1, Alfieri M.1, Nagore D.2, Del Rio L.2, Pascual J.2, Martínez A.2, Danese S.1,3

1Humanitas Clinical and Research Center, Department of Gastroenterology, Milan, Italy 2Progenika Biopharma SA, R&D Department, Derio, Spain 3Humanitas University, Department of Biomedical Sciences, Milan, Italy

P476: Sigmoidostomy or Hartman's procedure during laparoscopic subtotal colectomy for acute colitis complicating inflammatory bowel disease? A comparative study in 129 consecutive patientsECCO '17 Barcelona
Year: 2017
Authors:

Mege D.*1, Buskens C.2, Maggiori L.1, Stellingwerf M.2, Bemelman W.2, Panis Y.1

1Beaujon Hospital, Colorectal Surgery, Clichy, France 2AMC, Digestive Surgery, Amsterdam, Netherlands

P478: The current place of probiotics in treatment of pouchitis: systematic reviewECCO '17 Barcelona
Year: 2017
Authors:

Lichtenstein L., Avni I., Ben-Bassat O.

Rabin Medical Center, Gastroenterology, Petach Tikva, Israel

P479: Shifting the shunters in a paediatric inflammatory bowel disease population: thiopurine dose splitting versus allopurinol and thiopurine co-therapyECCO '17 Barcelona
Year: 2017
Authors:

Chadokufa S.*1,2, Baycheva M.2, Sawney T.3, Acton N.4, Sider S.1, Shah N.2, Huggett B.4, Dziubak R.2, Kiparrissi F.1

1Great Ormond Street Hospital, Gastro, London, United Kingdom 2Great Ormond Street Hospital, Paediatric Gastroenterology, London, United Kingdom 3Great Ormond Street Hospital, London, United Kingdom 4Great Ormond Street, London, United Kingdom

P480: Characteristics of drug-induced lupus 2° to anti-TNF agents in inflammatory bowel disease patients and evolution after switch to a second anti-TNFECCO '17 Barcelona
Year: 2017
Authors:

Mañosa M.*1, Corrales G.1, Olivares D.2, Vicuña M.3, Aguas M.4, Busquets D.5, Tosca J.6, Llaό J.7, Mesonero F.8, García-Tejero I.9, Ferreiro R.10, Cabré E.1, Domènech E.1

1Hospital Universitari Germans Trias i Pujol and CIBERehd, Gastroenterology, Badalona, Spain 2H Clínico San Carlos, Gastroenterology, Madrid, Spain 3Complejo Hospitalario de Navarra, Gastroenterolgy, Pamplona, Spain 4Hospital La Fe, Gastroenterology, Valencia, Spain 5Hospital universitari de Girona. Dr Trueta, Gastroenterology, Girona, Spain 6Hospital Clínic de Valencia, Gastroenterology, Valencia, Spain 7Hospital Santa Creu i Sant Pau, Gastroenterology, Barcelona, Spain 8H Ramon y Cajal, Gastroenterology, Madrid, Spain 9H Santa Lucia, Gastroenterology, Cartagena, Spain 10Hospital Universitario de Santiago, Gastroenterology, Santiago de Compostela, Spain

P481: Serum levels of infliximab associate with early mucosal healing in Crohn's disease: different “therapeutic window” between post-induction and maintenance treatmentECCO '17 Barcelona
Year: 2017
Authors:

Feng T.1, Chen B.1, Mao R.1, Ben-Horin S.2, Chen M.*1

1The First Affiliated Hospital of Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China 2Sheba Medical Center, Department of Gastroenterology, Tel Hashomer, Israel

P482: Early anti-TNF/immunomodulator therapy is associated with better clinical outcomes in Asian patients with Crohn's disease with poor prognostic factorsECCO '17 Barcelona
Year: 2017
Authors:

Oh E.H.*1, Oh K.1, Seo H.2, Chang K.2, Kim G.-U.2, Song E.M.2, Seo M.2, Lee H.-S.3, Kwon E.J.2,4, Hwang S.W.2,4, Park S.H.2,4, Yang D.-H.2, Kim K.-J.2,4, Byeon J.-S.2, Myung S.-J.2, Yang S.-K.2,4, Ye B.D.2,4

1University of Ulsan College of Medicine, Asan Medical Center, Department of Internal Medicine, Seoul, South Korea 2University of Ulsan College of Medicine, Asan Medical Center, Department of Gastroenterology, Seoul, South Korea 3University of Ulsan College of Medicine, Asan Medical Center, Health Screening and Promotion Center, Seoul, South Korea 4Asan Medical Center, University of Ulsan College of Medicine, Inflammatory Bowel Disease Center, Seoul, South Korea

P483: Relapse after discontinuation of the maintenance drug in patients with Ulcerative proctosigmoiditis: preliminary result of a prospective randomized trialECCO '17 Barcelona
Year: 2017
Authors:

Choi H.*1, Gweon T.-G.2, Lee B.-I.2, Lee K.-M.2, Kim S.-W.2, Kang S.-B.2, Ji J.-S.2, Han S.-W.2, Choi M.-G.2

1The Catholic University of Korea, Internal Medicine, Seoul, South Korea 2The Catholic University of Korea, Seoul, South Korea

P484: Dietary therapy using the Crohn's disease exclusion diet is a successful strategy for induction of remission in children and adults failing biological therapyECCO '17 Barcelona
Year: 2017
Authors:

Sigall Boneh R.*1, Sarbagili Shabat C.1, Boaz M.2,3, Levine A.1,4, Chermesh I.5, Ben Avraham S.1, Cohen Dolev N.1

1Wolfson Medical Center, Pediatric Gastroenterology and Nutrition Unit, Tel Aviv, Israel 2Wolfson Medical Center, Epidemiology and Research Unit, Tel Aviv, Israel 3Ariel University, Nutrition School of Health Sciences, Ariel, Israel 4Tel Aviv University, Tel Aviv, Israel 5Rambam health care campus, Gastroenterology, Haifa, Israel

P485: Dosing infliximab in Crohn's disease: Is adjustment for body size justified?ECCO '17 Barcelona
Year: 2017
Authors:

Grisic A.-M.*1,2, Huisinga W.3, Reinisch W.4, Kloft C.1

1Freie Universitaet Berlin, Department of Clinical Pharmacy and Biochemistry, Berlin, Germany 2Graduate Research Training Program PharMetrX, Berlin, Germany 3Universitaet Potsdam, Institute of Mathematics, Potsdam, Germany 4Medical University of Vienna, Department for Gastroenterology and Hepatology, Vienna, Austria

P486: Immunization status of children and adolescents with inflammatory bowel disease or autoimmune hepatitis in GermanyECCO '17 Barcelona
Year: 2017
Authors:

Cagol L.1, Frivolt K.2, Krahl A.3, Förster N.3, Lainka E.4, Gerner P.5, Ney D.6, Vermehren J.7, Trenkel S.8, Radke M.8, Koletzko S.2, Posovszky C.*1

1University Medical Center Ulm, Department for Pediatric and Adolescent Medicine, Ulm, Germany 2Ludwigs-Maximilians-University, Dr. von Hauner Children's Hospital, Munich, Germany 3Darmstädter Kinderkliniken Prinzessin Margaret, Darmstadt, Germany 4University Medical Center Essen, Department for Pediatric and Adolescent Medicine, Essen, Germany 5University Medical Center Freiburg, Department for Pediatric and Adolescent Medicine, Freiburg, Germany 6Katholisches Kinderkrankenhaus Wilhelmsstift, Hamburg, Germany 7University Medical Center Regensburg, Department for Pediatric and Adolescent Medicine, Regensburg, Germany 8Klinikum Westbrandenburg, Department for Pediatric and Adolescent Medicine, Potsdam, Germany

P487: Effectiveness and safety of CT-P13 under routine care in paediatric patients with inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Choe Y.H.*1, Yang H.R.2, Moon J.S.3, Ryoo E.4, Kim S.5, Lee J.H.6, Kim H.J.7, Park J.H.8, Kim M.J.9, Lee S.J.10, Lee S.Y.10

1Samsung medical center, Sungkyunkwan University School of Medicine, Department of Pediatrics, Seoul, South Korea 2Seoul National University Bundang Hospital, Department of Pediatrics, Seongnam, South Korea 3Seoul National University Hospital, Seoul, South Korea 4Gachon University Gil Medical center, Incheon, South Korea 5Severance Children's Hospital, Yonsei University College of Medicine, Department of Pediatrics, Seoul, South Korea 6Seoul Song Do Colorectal Hospital, Department of Internal Medicine, Seoul, South Korea 7Kyung Hee University College of Medicine, Department of Internal Medicine, Seoul, South Korea 8Pusan National University Yangsan Hospital, Pusan, South Korea 9Inje University Ilsan Paik Hospital, Department of Pediatrics, Goyang, South Korea 10CELLTRION, Inc., Incheon, South Korea